Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma

Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma

Abstract Background Epacadostat is a potent inhibitor of the immunosuppressive indoleamine 2,3-dioxygenase 1 (IDO1) enzyme. We present phase 1 results from a phase 1/2 clinical study of epacadostat in combination with ipilimumab, an anti-cytotoxic T-lymphocyte-associated protein 4 antibody, in advan...

Full description

Bibliographic Details
Main Authors: Geoffrey T. Gibney, Omid Hamid, Jose Lutzky, Anthony J. Olszanski, Tara C. Mitchell, Thomas F. Gajewski, Bartosz Chmielowski, Brent A. Hanks, Yufan Zhao, Robert C. Newton, Janet Maleski, Lance Leopold, Jeffrey S. Weber
Format: Article
Language:English
Published: BMJ Publishing Group 2019-03-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Epacadostat
IDO1
Immune checkpoint inhibition
Ipilimumab
Melanoma
Online Access:http://link.springer.com/article/10.1186/s40425-019-0562-8

Internet

http://link.springer.com/article/10.1186/s40425-019-0562-8

Similar Items